**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An 88-year-old man experienced lack of efficacy following treatment with norepinephrine and vasopressin for hypotension and septic shock.

The man, who had a history of coronary artery disease, type 2 diabetes mellitus, hypertension, acute respiratory distress syndrome (ARDS) and had been receving treatment with lisinopril, presented to a clinic in the USA with a 3-day history of cough and shortness of breath. On presentation, he had fever, tachycardia and tachypnoea with oxygen saturation of 48% on room air. He was transferred to the emergency department and was intubated. Laboratory investigations revealed lymphopenia, leukocytosis, mildly increased creatinine and markedly increased CRP and D-dimer. A CT chest angiogram demonstrated diffuse perihilar ground-glass interstitial opacities with consolidation at lung bases. A nasopharyngeal swab was sent for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR. He promptly received crystalloid resuscitation and broad-spectrum antibiotics \[*specific drug not stated*\] and was admitted to the ICU. Thereafter, he became hypotensive and developed septic shock. Consequently, he received vasopressin and norepinephrine \[*dosages and routes not stated*\]. His ventilator treatment was started with high positive end-expiratory pressure and low FIO2, based on ARDSnet protocol. On ICU day 2, the SARS-CoV-2 PCR result was found to be positive. Therefore, he started receiving an off-label treatment with hydroxychloroquine and azithromycin. He also received neuromuscular blocker therapy \[*details not stated*\] for ventilator dyssynchrony and was placed in prone position to improve dorsal lung aeration. Throughout the day, his vasopressor requirements worsened severely. A transthoracic echocardiography showed an ejection fraction of 61%, normal right ventricular systolic function and an estimated right ventricular systolic pressure of 57mm Hg. Noninvasive cardiac output monitor showed severely reduced vascular resistance and high cardiac output. Although corticosteroids are not recommended for COVID-19, stress dose methylprednisolone was added for refractory septic shock. Angiotensin-II \[Ang-2\] was then added as a third vasopressor. After the initiation of angiotensin-II therapy, a considerable reduction in norepinephrine and vasopressin requirements was observed.

On ICU day 3, the man was weaned of all vasopressors. His respiratory status improved. He had right upper extremity catheter-associated deep vein thrombosis and received therapeutic heparin. On ICU day 4, neuromuscular blocker and methylprednisolone were discontinued. On ICU day 7, he developed acute kidney injury, but did not require dialysis. He remained off vasopressor with stable ventilator requirement. On ICU day 9, his family elected to transition to comfort measures and he died after compassionate extubation \[*cause of death not stated*\].
